Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Cited by (1,018)

Items 801–900 of 1,018

1. Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
   Takeshi Yoshida, Guolin Zhang, Eric B. Haura · 2010 · Biochemical Pharmacology
2. Lung Cancer
   Stefan Hammerschmidt, Hubert R. W. Wirtz · 2009 · Deutsches Ärzteblatt international
3. An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease
   Joseph Kamel Salama, Steven J. Chmura, Neil Mehta, Kamil M. Yenice, Walter Michael Stadler, Everett E. Vokes, Daniel J. Haraf, Samuel Hellmän, Ralph R. Weichselbaum · 2008 · Clinical Cancer Research
4. Failures in Phase III: Causes and Consequences
   Boštjan Šeruga, Alberto Ocaña, Eitan Amir, Ian F. Tannock · 2015 · Clinical Cancer Research
5. The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade
   Nisancioglu, Maya H., Betsholtz, Christer, Genové, Guillem · 2010 · Cancer Research
6. ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
   Giorgio V. Scagliotti, Rolf Arno Stahel, Rafael Rosell, N. Thatcher, Jean‐Charles Soria · 2012 · European Journal of Cancer
7. Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer
   Emer O. Hanrahan, Anderson Joseph Ryan, Helen Mann, Sarah J. Kennedy, Peter B. Langmuir, Ronald B. Natale, Roy S. Herbst, Bruce Evan Johnson, John Victor Heymach · 2009 · Clinical Cancer Research
8. Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer
   Hester van Cruijsen, Marielle I. Gallegos Ruiz, Paul van der Valk, Tanja D. de Gruijl, Giuseppe Giaccone · 2009 · BMC Cancer
9. Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions
   Alberto Ocaña, Eitan Amir, Francisco Vera, Elizabeth A. Eisenhauer, Ian F. Tannock · 2010 · Journal of Clinical Oncology
10. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials
    Wei‐Xiang Qi, Zan Shen, Lina Tang, Yang Yao · 2014 · British Journal of Clinical Pharmacology
11. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer☆
    Justin C. Chura, K VANISEGHEM, L DOWNSJR, Linda F. Carson, P JUDSON · 2007 · Gynecologic Oncology
12. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
    Richard Michael Zuniga, Roy Torcuator, Rajan Jain, John E. Anderson, Thomas J. Doyle, Lonni R Schultz, Tom Mikkelsen · 2010 · Journal of Neuro-Oncology
13. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer
    Baohui Han, Qingyu Xiu, Huimin Wang, Jie Shen, Aiqin Gu, Yi Luo, Chunxue Bai, Shuliang Guo, Wenchao Liu, Zhixiang Zhuang et al. · 2011 · Journal of Thoracic Oncology
14. The malignant clone and the bone-marrow environment
    Klaus Podar, Paul Gerard Guy Richardson, Teru Hideshima, Dharminder Chauhan, Kenneth Carl Anderson · 2007 · Best Practice & Research Clinical Haematology
15. The angiogenic process as a therapeutic target in cancer
    Esther Bridges, Adrian Llewellyn Harris · 2011 · Biochemical Pharmacology
16. Chemotherapy for Lung Cancer in the Era of Personalized Medicine
    Seung Hyeun Lee · 2018 · Tuberculosis & respiratory diseases
17. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis
    Mao‐Mao An, Zui Zou, Hui Shen, Ping Liu, Meng Li Chen, Yong Bing Cao, Yuan Ying Jiang · 2010 · European Journal of Clinical Pharmacology
18. Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?
    Alberto J. Montero, Mauricio Escobar, Gilberto De Lima Lopes Jr., Stefan Glück, Charles L. Vogel · 2011 · Current Oncology Reports
19. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer
    Tina Cascone, Li Xu, Heather Yan Lin, Wenbin Liu, Hai Thanh Tran, Yuan Liu, Kathryn Howells, Vincent Haddad, Emer O. Hanrahan, Monique B. Nilsson et al. · 2017 · Clinical Cancer Research
20. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
    Takehito Shukuya, Takeharu Yamanaka, Takashi Seto, Haruko Daga, Kōichi Goto, Hideo Saka, Shunichi Sugawara, Toshiaki Takahashi, Soichiro Yokota, Hiroyasu Kaneda et al. · 2015 · The Lancet Oncology
21. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    David A. Reardon, Annick Desjardins, Katherine B. Peters, James J. Vredenburgh, Sridharan Gururangan, John Howard Sampson, Roger E. McLendon, James E. Herndon, April D. Sykes, Stevie Threatt et al. · 2011 · Cancer
22. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC
    Francesca Casaluce, Assunta Sgambato, Paolo Maione, Antônio Rossi, Carmine Ferrara, Alba Napolitano, Giovanni Palazzolo, Fortunato Ciardiello, Cesare Gridelli · 2013 · Targeted Oncology
23. New advances in targeted gastric cancer treatment
    Daniela Cornelia Lazăr, Sorina Maria Tăban, Mărioara Cornianu, Alexandra Corina Faur, Adrian Goldiș · 2016 · World Journal of Gastroenterology
24. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial
    Kohei Otsubo, Junji Kishimoto, Masahiko Ando, Hirotsugu Kenmotsu, Yuji Minegishi, Hidehito Horinouchi, Terufumi Kato, Eiki Ichihara, Masashi Kondo, Shinji Atagi et al. · 2022 · European Respiratory Journal
25. Bevacizumab in Non–Small Cell Lung Cancer
    Alan B. Sandler · 2007 · Clinical Cancer Research
26. How to improve exposure of tumor cells to drugs — Promoter drugs increase tumor uptake and penetration of effector drugs
    Fabrizio Marcucci, Angelo Corti · 2011 · Advanced Drug Delivery Reviews
27. The Biology of Brain Metastasis
    Robert R. Langley, Isaiah J Fidler · 2012 · Clinical Chemistry
28. Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung
    Maria Jose Pajares, Jackeline Agorreta, Marta Larráyoz, Aurélien Vesin, Teresa Ezponda, Isabel Zudaire, Wenceslao Torre, María D. Lozano, Elisabeth M. Brambilla, Christian Brambilla et al. · 2012 · Journal of Clinical Oncology
29. Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
    Anthony W. Tolcher, Christopher J. Sweeney, Kyri P. Papadopoulos, Amita Patnaik, Elena Gabriela Chiorean, Alain C. Mita, Kamalesh Kumar Sankhala, Eric S. Furfine, Jochem Gokemeijer, Lisa C. Iacono et al. · 2011 · Clinical Cancer Research
30. A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
    Brian I. Rini, Jorge Alberto Garcia, Matthew M. Cooney, Paul J. Elson, Allison Janine Tyler, Kristi Beatty, Joseph A. Bokar, Tarek M. Mekhail, Ronald M. Bukowski, George Thomas Budd et al. · 2009 · Clinical Cancer Research
31. Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma
    Elisabeth Naschberger, Andrea Liebl, Vera Simone Schellerer, Manuela Schütz, Nathalie Britzen‐Laurent, Patrick Kölbel, Ute Schaal, Lisa Haep, Daniela Regensburger, Thomas Wittmann et al. · 2016 · Journal of Clinical Investigation
32. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies.
    Charles B. Simone, Stuart H. Burri, John Henry Heinzerling · 2015 · PubMed Central
33. Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer
    David Robert Spigel, F. Anthony Greco, John D. Zubkus, Patrick B. Murphy, Ruben A. Saez, Cindy P. Farley, Denise Aysel Yardley, Howard A. Burris, John Daniel Hainsworth · 2009 · Journal of Thoracic Oncology
34. Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers
    Ronald J Scheff, Bryan James Schneider · 2013 · Seminars in Interventional Radiology
35. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review
    George E. Pentheroudakis, F. Anthony Greco, Nicholas A. Pavlidis · 2008 · Cancer Treatment Reviews
36. Cardiac Effects of Anticancer Therapy in the Elderly
    Melissa Kate Accordino, Alfred I. Neugut, Dawn L. Hershman · 2014 · Journal of Clinical Oncology
37. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
    David A. Reardon, Patrick Yung Wen, Annick Desjardins, Tracy T. Batchelor, James J. Vredenburgh · 2008 · Expert Opinion on Biological Therapy
38. Gastric cancer and the epoch of immunotherapy approaches
    Elena Niccolai, Antonio Taddei, Domenico Prisco, Amedeo Amedei · 2015 · World Journal of Gastroenterology
39. Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice
    Jacoby, Jörg J., Erez, Baruch, Korshunova, Maria V., Williams, Ryan R., Furutani, Kazuhisa, Takahashi, Osamu, Kirkpatrick, Lynn, Lippman, Scott M., Powis, Garth, O'Reilly, Michael S. et al. · 2010 · Journal of Thoracic Oncology
40. The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
    Limor Amit, Irit Ben‐Aharon, Liat Vidal, Leonard Leibovici, Salomon Marcello Stemmer · 2013 · PLoS ONE
41. Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments
    Giulio Rossi, Giuseppe Pelosi, Paolo Graziano, Mattia Barbareschi, Mauro Giulio Papotti · 2009 · International Journal of Surgical Pathology
42. Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
    Channing Judith Paller, Penelope A. Bradbury, S. Percy Ivy, Lesley Seymour, Patricia Mucci LoRusso, Laurence H. Baker, Larry Rubinstein, Erich Huang, Deborah E. Collyar, Susan G. Groshen et al. · 2014 · Clinical Cancer Research
43. Integration of Molecular Profiling into the Lung Cancer Clinic
    William J. Pao, Mark G. Kris, Anthony John Iafrate, Marc Ladanyi, Pasi Antero Janne, Ignacio Ivan Wistuba, Ryn Miake-Lye, Roy S. Herbst, David Paul Carbone, Bruce Evan Johnson et al. · 2009 · Clinical Cancer Research
44. Whole-Tumor Perfusion CT in Patients with Advanced Lung Adenocarcinoma Treated with Conventional and Antiangiogenetic Chemotherapy: Initial Experience
    Francesco Fraioli, Michele Anzidei, Fulvio Zaccagna, Maria Luisa Mennini, Goffredo Serra, Bruno Gori, Flavia Longo, Carlo Catalano, Roberto Passariello · 2011 · Radiology
45. Identification of Secreted Proteins that Mediate Cell-Cell Interactions in an In vitro Model of the Lung Cancer Microenvironment
    Zhong Li, Jonathon D. Roybal, Raghothama Chaerkady, Wan Zhang, Kuicheon C. Choi, Cristina A. Alvarez, Hai Thanh Tran, Chad J. Creighton, Shaoyu Yan, Robert M. Strieter et al. · 2008 · Cancer Research
46. Angiogenesis and antiangiogenic agents in cervical cancer
    Federica Tomao, Federica Tomao, Luigi Rossi, Eleonora Zaccarelli, Davide Caruso, Federica Zoratto, Pierluigi Benedetti Panici, Anselmo Papa · 2014 · OncoTargets and Therapy
47. Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
    Anil Bagri, Hosein Kouros‐Mehr, Kevin G. Leong, Gregory D. Plowman · 2010 · Trends in Molecular Medicine
48. RAS interaction with PI3K p110α is required for tumor-induced angiogenesis
    Miguel Manuel Murillo, Santiago Zelenay, Emma L. Nye, Esther Castellano, François Lassailly, Gordon Stamp, Julian Downward · 2014 · Journal of Clinical Investigation
49. Advances in Target Therapy for Lung Cancer
    Tetsuya Mitsudomi · 2009 · Japanese Journal of Clinical Oncology
50. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond
    Rohit Moudgil, Edward T.H. Yeh · 2016 · Canadian Journal of Cardiology
51. Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework
    Darius Lakdawalla, Jason T. Shafrin, Ningqi Hou, Desi Peneva, Seanna M. Vine, Jinhee Park, Jie Zhang, Ron Brookmeyer, Robert A. Figlin · 2017 · Value in Health
52. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
    Chinami Masuda, Mieko Yanagisawa, Keigo Yorozu, Mitsue Kurasawa, Koh Furugaki, Nobuyuki Ishikura, Toshiki Iwai, Masamichi Sugimoto, Kaname Yamamoto · 2017 · International Journal of Oncology
53. Small-molecule compounds target paraptosis to improve cancer therapy
    Yujia Wang, Xiang Wen, Nan Zhang, Lian Wang, Dan Hao, Xian Li Jiang, Gu He · 2019 · Biomedicine & Pharmacotherapy
54. Dual Targeting of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor Pathways: Rationale and Clinical Applications for Non-Small-Cell Lung Cancer
    Lauren A. Byers, John Victor Heymach · 2007 · Clinical Lung Cancer
55. Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer
    Benjamin Besse, L. Claire Tsao, Debra T. Chao, Ying Fang, Jean‐Charles Soria, Salah Almokadem, Chandra Prakash Belani · 2012 · Annals of Oncology
56. Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine
    Gabriella Lupo, Nunzia Caporarello, Melania Olivieri, Martina Cristaldi, Carla Motta, Vincenzo Bramanti, Roberto Avola, Mario Salmeri, Ferdinando Nicoletti, Carmelina Daniela Anfuso · 2017 · Frontiers in Pharmacology
57. Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
    Kalliopi Domvri, Paul Zarogoulidis, Kaid Darwiche, Robert F. Browning Jr, Qiang Li, J. Francis Turner, Ioannis P. Kioumis, Dionysios Spyratos, Κonstantinos Porpodis, Antonis Papaiwannou et al. · 2013 · Journal of Cancer
58. Endothelial Heparan Sulfate in Angiogenesis
    Mark M. Fuster, Lianchun Wang · 2010 · Progress in molecular biology and translational science
59. Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape
    Sumanta Kumar Pal, Robert A. Figlin, Karen L. Reckamp · 2010 · Molecular Cancer Therapeutics
60. Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
    Martin P. Barr, Steven G. Gray, Kathy A. Gately, Emily Hams, Padraic G. Fallon, Anthony Mitchell Davies, Derek J. Richard, Graham P. Pidgeon, Kenneth John O'Byrne · 2015 · Molecular Cancer
61. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
    Shirish M. Gadgeel, James P. Stevenson, Corey Jay Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza Cosca Villaruz, Matthew A. Gubens, Ralph J. Hauke, James Chih‐Hsin Yang et al. · 2018 · Lung Cancer
62. MicroRNAs in non‐small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential
    Hannah Elizabeth Petrek, Ai‐Ming Yu · 2019 · Pharmacology Research & Perspectives
63. Targeting Angiogenesis in Head and Neck Cancer
    Tanguy Y. Seiwert, Ezra E.W. Cohen · 2008 · Seminars in Oncology
64. Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy
    Pek Keng Koh, Corinne Faivre Finn, Fiona Helen Blackhall, Dirk De Ruysscher · 2011 · Cancer Treatment Reviews
65. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects
    Mariëtte H.W. Kappers, Joep H.M. van Esch, Stefan Sleijfer, AH Jan Danser, Anton H. van den Meiracker · 2009 · Journal of Hypertension
66. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
    Fiona A. Simpkins, Jerome L. Belinson, Peter Graham Rose · 2007 · Gynecologic Oncology
67. Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis
    Tsuyoshi Osawa, Masashi Muramatsu, Feng Wang, Rika Tsuchida, Tatsuhiko Kodama, Takashi Minami, Masabumi Shibuya · 2011 · Proceedings of the National Academy of Sciences
68. Effect of eIF3a on Response of Lung Cancer Patients to Platinum-Based Chemotherapy by Regulating DNA Repair
    Ji‐Ye Yin, Jie Shen, Zizheng Dong, Qiong Huang, Mei-Zuo Zhong, D Feng, Hong-Hao Zhou, Jian‐Ting Zhang, Zhaoqian Liu · 2011 · Clinical Cancer Research
69. Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broad-spectrum agents
    Gabriel Limaverde‐Sousa, Cinthya Sternberg, Carlos Gil Ferreira · 2013 · Cancer Treatment Reviews
70. Antibodies in oncology
    Vinochani Pillay, Hui Kong Gan, Andrew Mark Scott · 2011 · New Biotechnology
71. Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer
    Daniel Morgensztern, Roy S. Herbst · 2016 · Clinical Cancer Research
72. Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?
    Panagiotis Baxevanos, Giannis Mountzios · 2018 · Annals of Translational Medicine
73. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
    Chengdi Wang, Wenliang Qiao, Yuting Jiang, Min Zhu, Jun Shao, Tao Wang, Dan Liu, Weimin Li · 2019 · Journal of Cellular Physiology
74. Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)
    Angela M. Davies, Kari Chansky, Primo N. Lara, Paul H. Gumerlock, John J. Crowley, Kathy S. Albain, Stanley J. Vogel, David R. Gandara · 2009 · Journal of Thoracic Oncology
75. The Role of Desmoglein-3 in the Diagnosis of Squamous Cell Carcinoma of the Lung
    Cemile Dilara Savci-Heijink, Farhad Kosari, Marie-Christine Aubry, Bolette L. Caron, Zhifu Sun, Ping Yang, George Vasmatzis · 2009 · American Journal Of Pathology
76. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases
    Motomasa Furuse, Shinji Kawabata, Toshihiko Kuroiwa, Shin‐Ichi Miyatake · 2010 · Journal of Neuro-Oncology
77. Treatment of metastatic cervical cancer: Future directions involving targeted agents
    Iván Díaz-Padilla, Bradley J. Monk, Helen J MacKay, Ana Oaknin · 2012 · Critical Reviews in Oncology/Hematology
78. Approved monoclonal antibodies for cancer therapy
    Michael M. Boyiadzis, Kenneth A. Foon · 2008 · Expert Opinion on Biological Therapy
79. Targeted therapies in bladder cancer—an update
    Peter C. Black, Piyush Kumar Agarwal, Colin P. Dinney · 2007 · Urologic Oncology Seminars and Original Investigations
80. Cannabinoids as Anticancer Drugs
    Robert Ramer, Burkhard Hinz · 2017 · Advances in pharmacology
81. The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
    Alison Catherine Backen, Andrew G. Renehan, Andrew R. Clamp, Carlo Berzuini, Cong Zhou, Amit M. Oza, Selina Bannoo, Stefan J. Scherer, Rosamonde Elizabeth Banks, Caroline Dive et al. · 2014 · Clinical Cancer Research
82. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
    Rebecca Lynn Stone, Anil K. Sood, Robert Louis Coleman · 2010 · The Lancet Oncology
83. Aldolase A promotes proliferation and G 1 /S transition via the EGFR/MAPK pathway in non‐small cell lung cancer
    Hailu Fu, Huijun Gao, Xiaoyu Qi, Lei Zhao, Donghua Wu, Yuxin Bai, Huimin Li, Xuan Liu, Jun X. Hu, Shujuan Shao · 2018 · 癌症：英文版
84. Pro‐ and antiangiogenic therapies: current status and clinical implications
    Ruslan Rust, Christina Gantner, Martin E. Schwab · 2018 · The FASEB Journal
85. Takotsubo cardiomyopathy in cancer patients
    Aakash P. Desai, Arish Noor, Saurabh Joshi, Agnes S. Kim · 2019 · Cardio-Oncology
86. Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment
    Fatih Çiftçi, Ali Can Özarslan, İmran Cagri Kantarci, Aslıhan Yelkenci, Özlem Tavukçuoğlu, Mansour Ghorbanpour · 2025 · Pharmaceutics
87. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs
    Howard A. Burris · 2009 · Oncogene
88. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors
    Thomas E. Stinchcombe, Mark A. Socinski, Christine Marie Walko, Bert H. O’Neil, Frances A. Collichio, Anastasia Ivanova, Hua Mu, Michael Hawkins, Richard M. Goldberg, Celeste M Lindley et al. · 2007 · Cancer Chemotherapy and Pharmacology
89. Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies
    Sai‐Hong Ignatius Ou, Jason A. Zell · 2009 · Journal of Thoracic Oncology
90. Vascular Endothelial Growth Factor in Acute Lung Injury and Acute Respiratory Distress Syndrome
    Shaney Louise Barratt, Andrew R L Medford, Ann Millar · 2013 · Respiration
91. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer
    Autumn L. Jackson, Bing Rong Zhou, William Y. Kim · 2010 · Expert Opinion on Therapeutic Targets
92. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
    Haiquan Chen, Xinghua Cheng · 2014 · OncoTargets and Therapy
93. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
    Robert Charles Doebele, Paul Conkling, Anne M. Traynor, Gregory A. Otterson, Yanyan Zhao, Sven Wind, Peter Stopfer, Rolf Kaiser, D. Ross Camidge · 2012 · Annals of Oncology
94. New modalities of cancer treatment for NSCLC: focus on immunotherapy
    Marianne J Davies · 2014 · Cancer Management and Research
95. Targeted therapies in the treatment of advanced/metastatic NSCLC
    Athanasios G. Pallis, Lucile Serfass, R. Dziadziuszko, Jan P. van Meerbeeck, Dean Anthony Fennell, D. Lacombe, J. Welch, Cesare Gridelli · 2009 · European Journal of Cancer
96. What is the risk of intracranial bleeding during anti-VEGF therapy?
    Craig P. Carden, James Larkin, Mark Andrew Rosenthal · 2008 · Neuro-Oncology
97. Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer
    Do Joong Park, Nicholas J. Thomas, Changhwan Yoon, Sam S. Yoon · 2014 · Gastric Cancer
98. Prolonged Survival of Patients With Non–Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era
    Jonathan Wesley Riess, Seema Nagpal, Michael Iv, Michael Zeineh, Matthew A. Gubens, Kavitha J. Ramchandran, Joel W. Neal, Heather A. Wakelee · 2014 · Clinical Lung Cancer
99. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer
    Hiroyuki Y. Suzuki, Mitsuro Fukuhara, Takumi Yamaura, Satoshi Mutoh, Naoyuki Okabe, Hiroshi Yaginuma, Takeo Hasegawa, Atsushi Yonechi, Jun Osugi, Mika Hoshino et al. · 2013 · Journal of Translational Medicine
100. Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC
     Fan-Wei Peng, Xuan Ji, Ting-Ting Wu, Jia‐Yu Xue, Ziwei Ren, Dake Liu, Xiuqi Wang, Xin-Hang Chen, Jiawei Zhang, Yungen Xu et al. · 2015 · European Journal of Medicinal Chemistry